Vascular access thrombosis
and interventions in patients missing hemodialysis sessions.
Predictive measures of vascular access thrombosis
: a prospective study.
A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis. Hemodial Int 2009; 13(1): 19-26.
The role of endothelial nitric oxide synthase gene G894T and intron 4 VNTR polymorphisms in hemodialysis patients with vascular access thrombosis. Anatolian Cardiology Journal 2014; 14: 239-43.
(2007) demonstrated that in 24 hemodialysis facilities in The Netherlands, a two-step quality improvement program, which included vascular access education, surveillance, and monitoring protocols based on KDOQI guidelines, improved the knowledge, skill, and performance of hemodialysis unit staff; increased the prevalence of fistula placement (61% to 64%, p < 0.01) and early detection of vascular access complications (0.39 to 0.50 interventions per patient/year, p < 0.001), and decreased the incidence of hemodialysis vascular access thrombosis (0.41 per patient/year).
Vascular access thrombosis was the most prevalent reported complication pre- and post-intervention, which may indicate the need for education in assessment and surveillance techniques to detect early complications
The HD patients were allocated into two subgroups, according to the occurrence or not of a previous episode of vascular access thrombosis
(VAT) (with and without VAT).
The vascular access thrombosis
was managed by another ipsilateral proximally brachiocephalic arteriovenous anastomosis which was used directly, due to already maturation of the cephalic vein.
Huang, "C-reactive protein predicts vascular access thrombosis
in hemodialysis patients," Blood Purification, vol.
During 3 years of self-care hemodialysis, persistent complications of vascular access thrombosis occurred.
Vascular access-related complications can result in morbidity (Jindal et al., 1999), with vascular access thrombosis the most frequent cause (Brunet et al., 1995).
One adverse effect that has been attributed to rHuEPO therapy is an increased incidence of vascular access thrombosis
. It was anticipated during clinical trials of rHuEPO that the increased viscosity of the blood caused by an increased hematocrit (Hct) would result in more episodes of access thrombosis.